JW Life Science is the first known Peramivir drug to win a generic for exclusivity.

It is known to have been applied by JW Life Science's premium technology. Premix preparation is an injection that does not need to be diluted with saline water and is convenient to use. However, GC Pharma and Chong Kun Dang were also allowed to impose premix sanctions in May, signaling competition.

The MFDS approved JW Life Sciences' Fluenpera on Wednesday. It is a premix formulation that does not require dilution, and can be used once. In particular, JW Life Science's premix technology is applied, and it is a multi-layered film plastic container filling injection.

Peramivir is a single in